Back to all bills
HR 1672119th CongressIntroduced
Maintaining Investments in New Innovation Act
Introduced: Oct 18, 2025
Standard Summary
Comprehensive overview in 1-2 paragraphs
The Maintaining Investments in New Innovation Act amends Social Security Act to extend exclusivity period for advanced drug products using genetically targeted technologies.
Key Points
- 1Extends qualifying single source drug exclusivity from 7 to 11 years for advanced drug products
- 2Defines advanced drug products as those using genetically targeted technology
- 3Amends section 1192(e) of Social Security Act
- 4Applies to drugs that modulate gene function or gene products
- 5Supports innovation in genetic medicine and biotechnology
- 6Balances exclusivity with access to innovative treatments
Impact Areas
Pharmaceutical industry and drug developmentGenetically targeted therapies and precision medicineMedicare and prescription drug coverageBiotechnology innovation and investmentPatient access to cutting-edge treatments
Generated by kwaipilot/kat-coder-pro:free on Nov 21, 2025